General Clinical Research Center logo
  Quick Help
Ann Melvin, MD
Associate Program Director, Research Subject Advocate Program

Office: CHRMC W-7871
Mailstop W-6605
(206) 987-2535
ann.melvin@seattlechildrens.org

NIH Guidance on When Data and Safety Monitoring Boards (DSMBs) are Needed

The NIH requires a data and safety monitoring board (DSMB) for Phase III clinical investigations (or any multi-site clinical trial) involving interventions that entail potential risk to participants. For phase I and II trials, a DSMB may be appropriate if the studies have multiple clinical sites, are blinded, or employ particularly high-risk interventions or vulnerable populations. The NCRR requires a DSMB for any investigation that places participants at significant risk.

The following table lists documents available from various NIH agencies.

Source Title
NIH Further Guidance On Data And Safety Monitoring
For Phase I And Phase II Investigations

(Notice: OD-00-038, June 5, 2000)
NIH Policy For Data And Safety Monitoring
(Notice: OD-98-084, June 10, 1998)
NCI Essential Elements of a Data and Safety Monitoring Plan for Clinical Investigations Funded by the National Cancer Institute
NH LBI Establishing Data and Safety Monitoring Boards (DSMBs) and Observational Study Monitoring Boards (OSMBs)
NH LBI Responsibilities of Data and Safety Monitoring Boards (DSMBs) Appointed by Participating Institutions
top | Site Credits NCRR Funded under NCRR Grant M01-RR-00037 Updated: 03/02/2006 11:41 AM
About the GCRC Applications Education and Career Development Resources for Clinical Research Participate in Clinical Studies